You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
BioPorto - Receives FDA clearance for NGAL test in the US
Meet and ask questions to CEO Tony Paré from Bioporto on 11 December at 13:00 CET.
The focus will be on FDA 510(k) clearance for the NGAL test in the United States. This is the first test to aid in assessing AKI (Acute Kidney Injury) risk for patients aged 3 months through 21 years. The test will be marketed as ProNephro AKI™ (NGAL). Bioporto expects that US sales through its distribution agreement with Roche Diagnostics GmbH will begin in the second half of 2024.
Disclaimer: HC Andersen Capital receives payment from Bioporto for a DigitalIR/Corporate Visibility and IR advisory agreement./Claus Thestrup 13:05 8/12-2023.